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Clinical ResearchAssociation of Beta-Blocker Therapy
at Discharge With Clinical Outcomes
in Patients With ST-Segment Elevation
Myocardial Infarction Undergoing Primary
Percutaneous Coronary InterventionJeong Hoon Yang, MD,*y Joo-Yong Hahn, MD,* Young Bin Song, MD,*
Seung-Hyuk Choi, MD,* Jin-Ho Choi, MD,* Sang Hoon Lee, MD,* Joo Han Kim, MD,z
Young-Keun Ahn, MD,z Myung-Ho Jeong, MD,z Dong-Joo Choi, MD,x
Jong Seon Park, MD,jj Young Jo Kim, MD,jj Hun Sik Park, MD,{ Kyoo-Rok Han, MD,#
Seung Woon Rha, MD,** Hyeon-Cheol Gwon, MD*
Seoul, Gwangju, Seongnam, and Daegu, South KoreaObjectives This study sought to investigate the association of beta-blocker therapy at discharge
with clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI) after
primary percutaneous coronary intervention (PCI).
Background Limited data are available on the efﬁcacy of beta-blocker therapy for secondary
prevention in STEMI patients.
Methods Between November 1, 2005 and September 30, 2010, 20,344 patients were enrolled in
nationwide, prospective, multicenter registries. Among these, we studied STEMI patients undergoing
primary PCI who were discharged alive (n ¼ 8,510). We classiﬁed patients into the beta-blocker
group (n ¼ 6,873) and no–beta-blocker group (n ¼ 1,637) according to the use of beta-blockers at
discharge. Propensity-score matching analysis was also performed in 1,325 patient triplets. The
primary outcome was all-cause death.
Results The median follow-up duration was 367 days (interquartile range: 157 to 440 days).
All-cause death occurred in 146 patients (2.1%) of the beta-blocker group versus 59 patients (3.6%)
of the no–beta-blocker group (p < 0.001). After 2:1 propensity-score matching, beta-blocker therapy
was associated with a lower incidence of all-cause death (2.8% vs. 4.1%, adjusted hazard ratio: 0.46,
95% conﬁdence interval: 0.27 to 0.78, p ¼ 0.004). The association with better outcome of beta-
blocker therapy in terms of all-cause death was consistent across various subgroups, including
patients with relatively low-risk proﬁles such as ejection fraction >40% or single-vessel disease.
Conclusions Beta-blocker therapy at discharge was associated with improved survival in STEMI
patients treated with primary PCI. Our results support the current American College of Cardiology/
American Heart Association guidelines, which recommend long-term beta-blocker therapy in
all patients with STEMI regardless of reperfusion therapy or risk proﬁle. (J Am Coll Cardiol Intv
2014;7:592–601) ª 2014 by the American College of Cardiology FoundationFrom the *Division of Cardiology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of
Medicine, Seoul, South Korea; yDepartment of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University
School of Medicine, Seoul, South Korea; zDivision of Cardiology, Department of Medicine, Chonnam National University
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593The American College of Cardiology (ACC)/American
Heart Association (AHA) guidelines recommend beta-
blockers for secondary prevention in patients with ST-
segment elevation myocardial infarction (STEMI) without
regard to reperfusion therapy (1). However, evidence sup-
porting this recommendation originated from studies con-
ducted before the introduction of reperfusion therapy or
studies in patients treated with ﬁbrinolysis (2,3). In the
present era of primary percutaneous coronary intervention
(PCI), there are no prospective randomized studies looking
at the effects of long-term beta-blocker therapy on clinical
outcomes in STEMI patients. Moreover, results from reg-
istry data and post-hoc analysis on beta-blocker therapy
in patients undergoing primary PCI are inconsistent (4,5).See page 602
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CI = conﬁdence intervalIn particular, the beneﬁcial effect of long-term beta-blocker
therapy has not been well established in patients with rela-
tively low risk, such as preserved left ventricular systolic
function or single-vessel disease. Therefore, we investigated
the association of beta-blocker therapy at discharge with
clinical outcomes in STEMI patients after primary PCI,
using data from a nationwide, large registry series dedicated
to MI.HR = hazard ratio
IQR = interquartile range
MACE = major adverse
cardiac events
PCI = percutaneous coronary
intervention
STEMI = ST-segment
elevation myocardial
infarction
TIMI = Thrombolysis InMethods
Study population. The study population was selected from
the KAMIR (Korean Acute Myocardial Infarction Regis-
try), and its successor, KorMI (Korea Working Group on
Myocardial Infarction) registry. The KAMIR is the ﬁrst
nationwide, prospective, multicenter online registry in pa-
tients presenting with acute MI from November 2005 to
December 2007 (6,7). The KAMIR was conducted at 52
university or community hospitals. The KorMI is the second
nationwide online registry, conducted at 53 university or
community hospitals from January 2008 to September 2010
(8). Participating centers of the 2 registries have high vol-
umes of patients with facilities for primary PCI and onsite
cardiac surgery. The protocols of the 2 prospective cohorts
were similar. Between November 2005 and September 2010,
20,344 consecutive patients with acute MI were prospectively
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2013, accepted December 1, 2013.data were collected by a trained study coordinator using a
standardized case report form and protocol. Angiographic
parameters such as TIMI (Thrombolysis In Myocardial
Infarction) ﬂow grade or ACC/AHA lesion type were
assessed by the operator. If necessary, additional information
was documented by contacting the principal investigators in
each hospital and/or by review of hospital records and tele-
phone interviews. Clinical follow-up was performed at 1, 6,
and 12 months in KAMIR and at 1, 6, 12, and 24 months in
the KorMI registry after the PCI procedure. These registries
were sponsored by the Korean Society of Cardiology and
managed by the Korean Working Group of Acute Myocar-
dial Infarction. The local institutional review board at each
hospital approved the study protocol.
Inclusion criteria for the present analysis were: 1) con-
secutive patients 18 years of age or older; 2) patients with
ST-segment elevation >1 mm in at least 2 contiguous leads
or presumably new left bundle
branch block with elevated car-
diac enzymes (troponin or myo-
cardial band fraction of creatine
kinase); and 3) patients under-
going primary PCI. Exclusion
criteria were: 1) in-hospital death;
and 2) missing beta-blocker in-
formation. Among the patients
registered, 8,510 were ﬁnally
included in this analysis. The
patient ﬂow of the study is shown
in Figure 1. Subjects were divided
by use of beta-blockers at dis-
charge into the beta-blocker group
and no–beta-blocker group.
PCI procedure. Coronary in-
terventions were performed ac-
cording to current standard
procedural guidelines. All patients received a 300-mg
loading dose of aspirin and a 300- to 600-mg loading dose
of clopidogrel before the coronary intervention unless they
had previously received these antiplatelet medications.
Anticoagulation therapy during PCI was performed ac-
cording to current practice guidelines by the Korean Society
of Interventional Cardiology. The treatment strategy and the
use of glycoprotein IIb/IIIa receptor inhibitors or intravas-
cular ultrasound were all left to the operator’s discretion.
Drug-eluting stents were used without restriction. Duration
of dual antiplatelet therapy was determined by the operators.
Deﬁnitions and outcomes. Primary PCI was deﬁned as
percutaneous coronary revascularization within 24 h of
symptom onset without antecedent treatment with a ﬁbri-
nolytic agent as the initial therapy (9,10). All-cause death
was deﬁned as any death during or after the procedure and
was considered to be of cardiac origin unless a deﬁnite
noncardiac cause could be established. Recurrent MI was
Myocardial Infarction
Figure 1. Scheme of Group Distribution in the Registry
KAMIR ¼ Korean Acute Myocardial Infarction Registry; KorMI ¼ Korea Working
Group on Myocardial Infarction; MI ¼ myocardial infarction; NSTEMI ¼ non–
ST-segment elevation myocardial infarction; STEMI ¼ ST-segment elevation
myocardial infarction.
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594deﬁned as recurrent symptoms with new electrocardio-
graphic changes compatible with MI or cardiac markers at
least twice the upper limit of normal (11). Any revasculari-
zation was deﬁned as revascularization on either target or
non-target vessels. All events were identiﬁed by the patient’s
physician and conﬁrmed by the principal investigator of each
hospital.
The primary outcome was all-cause death during follow-
up. Secondary outcomes included cardiac death, recurrent
MI, any revascularization with PCI or coronary artery
bypass graft, and major adverse cardiac events (MACE), a
composite of all-cause death, recurrent MI, and any revas-
cularization during follow-up.
Statistical analysis. Comparisons for continuous variables
were made using the t test or Wilcoxon rank-sum test when
applicable. Categorical data were tested using the chi-
square test. Survival curves were constructed using Kaplan-
Meier estimates and compared with the log-rank test. The
Cox proportional hazard model was used to compare the
risks of adverse cardiac events between the use of beta-
blockers and no use of beta-blockers. The propensity scores
were estimated using multiple logistic-regression analysis. A
full nonparsimonious model was developed that included
age, sex, hospital groups according to the number of enrolled
patients, hypertension, previous MI, previous PCI, left
ventricular ejection fraction, creatinine, use of aspirin, clo-
pidogrel, renin-angiotensin receptor blockade, spirono-
lactone and statins at discharge, infarct-related artery PCI
with stent, maximal stent diameter, use of vasopressor, and
intra-aortic balloon pump in Tables 1 and 2. A 2:1 matchingratio (beta-blocker group to no–beta-blocker group) was
used to retain a large sample, which maximizes the
study power while maintaining a balance in covariates be-
tween the 2 groups (12). Cox regression analysis using
triplets matched by a greedy algorithm and the nearest
available triplet-matching method among patients with an
individual propensity score was also performed to evaluate
the reduction in outcome risk. The covariate balance ach-
ieved by matching was assessed by calculating the absolute
standardized differences in covariates between the use of
beta-blockers and no use of beta-blockers. An absolute
standardized difference of <10% for the measured covariate
suggests appropriate balance between the groups. In the
propensity score-matched population, continuous variables
were compared with a 2-way analysis of variance or the
median regression test, as appropriate; categorical variables
were compared using McNemar or Bowker tests of sym-
metry, as appropriate; and the reduction in the risk of
outcome was compared by use of the stratiﬁed Cox regres-
sion model, with prognostic covariates having an absolute
standardized difference of >1.0% considered as candidate
variables for inclusion in the multivariate models because
the combination of regression adjustment in matched
samples generally produces the least biased estimate
(13,14). Cumulative incidence rates of individual clinical
outcomes and composite outcomes were estimated by the
Kaplan-Meier method and compared by the paired Pren-
tice-Wilcoxon test. Statistical analyses were performed
with SAS version 9.2 (SAS Institute Inc., Cary, North
Carolina). All tests were 2-tailed, and p < 0.05 was
considered statistically signiﬁcant.
Results
Baseline and procedural characteristics. OVERALL POP-
ULATION. Beta-blockers were prescribed at discharge to
6,873 patients (80.8%), but not prescribed to 1,637 patients
(19.2%). Baseline clinical characteristics are shown in
Table 1 and angiographic and procedural characteristics in
Table 2. Symptom onset to balloon time (beta-blocker group
vs. no–beta-blocker group: median: 267 min, interquartile
range [IQR]: 172 to 451 min vs. median: 260 min, IQR:
179 to 444 min, p ¼ 0.97) and door-to-balloon time
(median: 78 min, IQR: 58 to 110 min vs. median: 77 min,
IQR: 57 to 112 min, p ¼ 0.77) were similar in both groups.
Overall, patients in the no–beta-blocker group were higher-
risk subjects. Compared with patients in the beta-blocker
group, those in the no–beta-blocker group were older and
had a higher prevalence of previous MI, Killip class III,
low left ventricular ejection fraction, elevated serum creati-
nine, and post-procedural TIMI ﬂow grade of 0 to 1. In
addition, patients in the no–beta-blocker group were less
likely to receive aspirin, clopidogrel, renin-angiotensin sys-
tem blockade, statins, or PCI with a stent, but they were
Table 1. Baseline Patient Characteristics
Total Population Propensity-Matched Population
Beta-Blocker
Group
(n ¼ 6,873)
No–Beta-Blocker
Group
(n ¼ 1,637) p Value
Standardized
Difference
Beta-Blocker
Group
(n ¼ 2,650)
No–Beta-Blocker
Group
(n ¼ 1,325) p Value
Standardized
Difference
Age, yrs 62 (52–72) 65 (55–74) <0.001 19.6 66 (55–74) 65 (55–74) 0.11 –3.9
Male 5,182 (75.4) 1,217 (74.3) 0.38 –2.7 1,913 (72.2) 990 (74.7) 0.14 5.8
Enrolled patients per hospital <0.001 NA
<50 332 (4.8) 125 (7.6) 172 (6.5) 86 (6.5)
50–99 809 (11.8) 316 (19.3) 19.5 488 (18.4) 244 (18.4) 0
100–199 1,221 (17.8) 324 (19.8) 2.2 534 (20.2) 267 (20.2) 0
200 4,511 (65.6) 872 (53.3) –22.0 1,456 (54.9) 728 (54.9) 0
Systolic blood pressure, mm Hg 130 (110–146) 120 (100–140) <0.001 –19.1 120 (106–140) 120 (101–140) 0.99 2.0
Diastolic blood pressure, mm Hg 80 (70–90) 77 (61–90) <0.001 –16.8 80 (65–90) 79 (62–90) 0.41 2.8
Heart rate, beats/min 74 (64–83) 74 (62–87) 0.08 –2.0 74 (63–87) 74 (63–87) 0.99 –0.1
Medical history
Diabetes mellitus 1,645 (23.9) 403 (24.6) 0.56 2.9 679 (25.6) 328 (24.8) 0.95 –2.0
Hypertension 3,157 (45.9) 707 (43.2) 0.05 –5.8 1,158 (43.7) 574 (43.3) 0.74 –0.8
Dyslipidemia 725 (10.5) 141 (8.6) 0.02 –4.5 244 (9.2) 114 (8.6) 0.97 –2.2
Smoking 3,334 (48.5) 737 (45.0) 0.01 –7.2 1,217 (45.9) 600 (45.3) 0.89 –1.3
Chronic kidney disease 58 (0.8) 15 (0.9) 0.78 2.0 27 (1.0) 11 (0.8) 0.25 –2.1
Family history of CAD 547 (8.0) 121 (7.4) 0.44 –4.2 190 (7.2) 98 (7.4) 0.74 0.9
Previous history of MI 330 (4.8) 128 (7.8) <0.001 9.7 170 (6.4) 89 (6.7) 0.99 1.2
Previous history of PCI 285 (4.1) 83 (5.1) 0.10 1.8 127 (4.8) 56 (4.2) 0.21 –2.8
Previous CABG 18 (0.3) 9 (0.5) 0.06 4.3 10 (0.4) 9 (0.7) 0.20 3.7
Previous CVA 335 (4.9) 89 (5.4) 0.35 2.7 117 (4.4) 74 (5.6) 0.44 5.1
Previous history of heart failure 50 (0.8) 18 (1.1) 0.13 2.9 25 (0.9) 13 (1.0) 0.87 0.4
Killip class III on admission 745 (10.8) 256 (15.6) <0.001 14.3 392 (14.8) 193 (14.6) 0.66 –0.6
Left ventricular ejection fraction* 51 (44–59) 50 (42–59) <0.001 –11.8 50 (42–58) 50 (41–59) 0.99 –1.4
Serum creatinine, mg/dl 1.0 (0.8–1.1) 1.0 (0.8–1.2) <0.001 7.7 1.0 (0.8–1.2) 1.0 (0.8–1.2) 0.99 0
Medication at discharge
Aspirin 6,812 (99.1) 1,600 (97.7) <0.001 –9.5 2,616 (98.7) 1,304 (98.4) 0.47 –2.4
Clopidogrel 6,746 (98.2) 1,579 (96.5) <0.001 –9.8 2,575 (97.2) 1,285 (97.0) 0.97 –1.1
RAS blockade 6,101 (88.8) 1,128 (68.9) <0.001 –43.1 2,018 (76.2) 999 (75.4) 0.45 –1.8
Spironolactone 341 (5.0) 76 (4.6) 0.59 –0.2 130 (4.9) 61 (4.6) 0.77 –1.4
Statins 5,651 (82.2) 1,301 (79.5) 0.01 –6.5 2,143 (80.9) 1,067 (80.5) 0.97 –0.9
Values are median (interquartile range) or n (%). *Left ventricular ejection fraction was available in 7,804 patients (91.7%) (6,314 patients [91.9%] in beta-blocker group and 1,490 patients [91.0%] in no–
beta-blocker group).
CABG ¼ coronary artery bypass graft; CAD ¼ coronary artery disease; CVA ¼ cerebrovascular accident; MI ¼ myocardial infarction; NA ¼ not applicable; PCI ¼ percutaneous coronary intervention;
RAS ¼ renin-angiotensin system.
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595more likely to receive a stent with a small size diameter,
vasopressors, intra-aortic balloon pump, deﬁbrillator/car-
dioversion, or temporary pacemaker.
PROPENSITY-MATCHED POPULATION. After performing pro-
pensity-score matching for the entire population, a total of
1,325 matched triplets of patients were created (Tables 1
and 2). The C-statistic for the propensity score model was
0.68, suggesting that use of beta-blockers was relatively
random and that would make the analysis more reliable.
Symptom onset–to-balloon time (beta-blocker group vs. no–
beta-blocker group: median: 270 min, IQR: 179 to 454 min
vs. median 260 min, IQR: 178 to 435 min, p ¼ 0.41) anddoor-to-balloon time (median: 78 min, IQR: 59 to 112 min
vs. median: 77 min, IQR: 57 to 113 min, p ¼ 0.28) were
similar in both groups. There were no signiﬁcant differences
in baseline clinical, angiographic, and procedural character-
istics between the 2 groups for the propensity-matched
subjects. On the other hand, for nonincluded patients in
propensity-matched analysis, patients in the no–beta-blocker
group were higher-risk groups as expected (Online Tables 1
and 2).
Clinical outcomes. OVERALL POPULATION. The median
follow-up duration was 367 days (IQR: 157 to 440 days).
Table 3 shows cumulative clinical outcomes of the study
groups. All-cause death occurred in 205 patients (2.4%)
Table 2. Angiographic and Procedural Characteristics
Variables
Total Population Propensity-Matched Population
Beta-Blocker
Group
(n ¼ 6,873)
No–Beta-Blocker
Group
(n ¼ 1,637) p Value
Standardized
Difference
Beta-Blocker
Group
(n ¼ 2,650)
No–Beta-Blocker
Group
(n ¼ 1,325) p Value
Standardized
Difference
Infarct-related artery 0.05 0.85
Left main coronary artery 78 (1.1) 13 (0.8) –4.1 21 (0.8) 11 (0.8) 0.4
Left anterior descending 3,713 (54.0) 847 (51.7) 1,367 (51.6) 710 (53.6)
Left circumﬂex 657 (9.6) 143 (8.7) –1.9 227 (8.6) 114 (8.6) 0.1
Right coronary 2,425 (35.3) 634 (38.7) 3.0 1,035 (39.1) 490 (37.0) –4.3
No. of coronary arteries narrowed 0.52 2.8 0.22
Left main, complex 113 (1.6) 31 (1.9) 2.8 46 (1.7) 28 (2.1) 2.7
Left main, isolated 17 (0.2) 5 (0.3) 1.4 8 (0.3) 4 (0.3) 0
1-vessel disease 3,486 (50.7) 820 (50.1) 1,273 (48.0) 661 (49.9)
2-vessel disease 1,958 (28.5) 447 (27.3) –3.6 793 (29.9) 362 (27.3) –5.8
3-vessel disease 1,299 (18.9) 334 (20.4) 3.0 530 (20.0) 270 (20.4) 0.9
ACC/AHA B2/C lesion 5,406 (78.7) 1,305 (79.7) 0.35 2.8 2,087 (78.8) 1,058 (79.9) 0.27 2.7
Pre-procedural TIMI ﬂow grade on culprit vessel 0.74 0.24
0 or 1 5,074 (73.8) 1,208 (73.8) 1,971 (74.4) 984 (74.3)
2 805 (11.7) 183 (11.2) –2.9 339 (12.8) 153 (11.6) –3.9
3 994 (14.5) 246 (15.0) –0.3 340 (12.8) 188 (14.2) 3.9
Post-procedural TIMI ﬂow grade 0.007 0.32
0 or 1 189 (2.7) 61 (3.7) 95 (3.6) 51 (3.9)
2 282 (4.1) 88 (5.4) 5.5 123 (4.6) 68 (5.1) 2.2
3 6,402 (93.1) 1,488 (90.9) –7.2 2,432 (91.8) 1,206 (91.0) –2.6
PCI with stent 6,430 (93.6) 1,483 (90.6) <0.001 –9.1 2,451 (92.5) 1,210 (91.3) 0.18 –4.2
Maximal stent diameter 3.0 (3.0–3.5) 3.0 (3.0–3.5) 0.02 –7.3 3.0 (3.0–3.5) 3.0 (3.0–3.5) 0.65 –5.3
Total stent length, mm 24 (20–28) 25 (23–28) 0.12 3.5 24 (20–28) 25 (20–28) 0.08 4.5
Vasopressor 996 (14.5) 342 (20.9) <0.001 14.9 523 (19.7) 253 (19.1) 0.72 –1.6
Glycoprotein IIb/IIIa inhibitor 1,133 (16.5) 278 (17.0) 0.63 2.5 350 (13.2) 190 (14.3) 0.33 3.0
Intra-aortic balloon pump 224 (3.3) 102 (6.2) <0.001 12.3 132 (5.0) 71 (5.4) 0.98 1.7
Deﬁbrillator/cardioversion 232 (3.4) 85 (5.2) <0.001 8.2 128 (4.8) 61 (4.6) 0.47 –1.1
Temporary pacemaker 355 (5.2) 121 (7.4) <0.001 7.3 180 (6.8) 84 (6.3) 0.95 –1.9
Values are n (%) or median (interquartile range).
ACC/AHA ¼ American College of Cardiology/American Heart Association; PCI ¼ percutaneous coronary intervention; TIMI ¼ Thrombolysis In Myocardial Infarction.
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596during follow-up. The beta-blocker group had a signiﬁcantly
lower incidence of all-cause death (beta-blocker group vs.
no–beta-blocker group: 2.1% vs. 3.6%, unadjusted hazard
ratio [HR]: 0.52, 95% conﬁdence interval [CI]: 0.38 to 0.70,
p < 0.001) (Fig. 2). The incidence of cardiac death was
signiﬁcantly lower in the beta-blocker group than in the
no–beta-blocker group (1.1% vs. 2.4%, unadjusted HR:
0.41, 95% CI: 0.28 to 0.60, p < 0.001), whereas both groups
had comparable incidences of MI and any coronary revas-
cularization. Although all-cause death or MI occurred less
frequently in the beta-blocker group than in the no–beta-
blocker group (3.1% vs. 4.7%, unadjusted HR: 0.58, 95%
CI: 0.45 to 0.75, p < 0.001), there was no signiﬁcant dif-
ference between the 2 groups in the rates of MACE. To
reinforce the strength of the analysis, we compared the
clinical outcomes between excluded patients due to missing
information on beta-blocker and study population during
follow-up period, and there were no signiﬁcant differencesbetween the 2 groups in the rates of all-cause death and
MACE (Online Table 3).
PROPENSITY-MATCHED POPULATION. There were 128 all-
cause deaths with a median follow-up of 364 days in the
matched patients. Beta-blocker therapy was still associated
with a lower incidence of all-cause death in the matched
cohort of patients (2.8% vs. 4.1%, adjusted HR: 0.46, 95%
CI: 0.27 to 0.78, p ¼ 0.004) (Table 4, Fig. 3). Cardiac death
occurred less frequently in the beta-blocker group than in
the no–beta-blocker group (1.5% vs. 2.8%, adjusted HR:
0.39, 95% CI: 0.19 to 0.79, p ¼ 0.01). There were no dif-
ferences between the 2 groups in the rates of MI, any cor-
onary revascularization, and MACE. In the stratiﬁed Cox
regression model with prognostic covariates adjustment,
signiﬁcant predictors of all-cause death were age (HR: 1.06,
95% CI: 1.03 to 1.09, p < 0.001), left anterior descending
artery as the infarct-related artery (HR: 2.51, 95% CI: 1.36
Table 3. Clinical Outcomes in the Beta-Blocker Group Compared With
No–Beta-Blocker Group During Follow-Up Period (n ¼ 8,510)
Beta-Blocker
Group
(n ¼ 6,873)
No–Beta-Blocker
Group
(n ¼ 1,637)
Unadjusted
HR (95% CI) p Value
All-cause death 146 (2.1) 59 (3.6) 0.52 (0.38–0.70) <0.001
Cardiac death 76 (1.1) 40 (2.4) 0.41 (0.28–0.60) <0.001
Myocardial infarction 71 (1.0) 21 (1.3) 0.73 (0.45–1.20) 0.21
All-cause death or MI 212 (3.1) 77 (4.7) 0.58 (0.45–0.75) <0.001
Any coronary
revascularization
435 (6.3) 93 (5.7) 1.01 (0.80–1.26) 0.97
Major adverse
cardiac events*
599 (8.8) 153 (9.3) 0.84 (0.71–1.01) 0.06
Values are n (%) unless otherwise indicated. *Major adverse cardiac events included all-cause
death, recurrent myocardial infarction, and any revascularization with PCI or coronary artery
bypass graft.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Table 1.
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597to 4.65, p ¼ 0.003), and no use of beta-blocker at discharge
(HR: 2.19, 95% CI: 1.29 to 3.72, p ¼ 0.004).
Subgroup analysis. To determine whether the outcomes
according to beta-blocker therapy observed in the overall
population were consistent, we calculated the unadjusted
HR for death in various complex subgroups (Fig. 4). The
association with better outcome of beta-blocker therapy
in terms of all-cause death was consistent across various
subgroups including patients with relatively low-risk
proﬁle such as left ventricular ejection fraction >40% or
single-vessel disease. There were no signiﬁcant interactions
between the use of beta-blocker at discharge and all-cause
death among all of the subgroups. The association with
better outcome of beta-blocker therapy in terms of all-cause
death was also consistent across various subgroups in pro-
pensity-matched populations (Fig. 5).Figure 2. Kaplan-Meier Curves in Beta-Blocker Versus No–Beta-Blocker Groups i
(A) Kaplan-Meier curves for all-cause death in beta-blocker (solid line) versus no beta
events (MACE) in beta-blocker (solid line) versus no-beta-blocker (dashed line) groDiscussion
In the present study, we investigated the association of beta-
blocker therapy with clinical outcomes in STEMI patients
who underwent primary PCI using data from large, pro-
spective, multicenter registry series in Korea. Beta-blocker
therapy at discharge was associated with lower mortality, and
this result was maintained in propensity-matched pop-
ulations. Furthermore, the association with better outcome
of beta-blocker therapy in terms of all-cause death was
consistent across various subgroups.
Although outcomes of patients with MI have greatly
improved after the introduction of primary PCI, optimal
medical therapy after successful reperfusion in patients with
STEMI is very important (15). Beta-blockers have been
reported to reduce life-threatening arrhythmias, relieve
recurrent ischemia, and reduce mortality, including sudden
cardiac death, in studies performed in the pre-PCI era
(16–18). Based on this evidence, the ACC/AHA guidelines
recommend beta-blockers for secondary prevention in all
patients with STEMI unless absolutely contraindicated or
not tolerated (1). However, evidence supporting routine
beta-blocker therapy for secondary prevention is lacking in
the primary PCI era. There are no prospective randomized
studies addressing this issue, and results from non-
randomized studies are inconsistent (4,5). Moreover, pre-
vious studies had several major limitations such as relatively
small sample size or lower rates of use of thienopyridine
medication and stent, unlike the current practice. The
recently published observational REACH (Reduction
of Atherothrombosis for Continued Health) registry showed
that the use of beta-blockers was not associated with a lower
risk of adverse events in stable patients with a previous
history of MI (19). However, the REACH registry did notn Overall Populations
-blocker (dashed line) groups. (B) Kaplan-Meier curves for major adverse cardiac
ups.
Table 4. Clinical Outcomes in the Beta-Blocker Group Compared With
No–Beta-Blocker Group in Propensity-Matched Population During
Follow-Up Period (n ¼ 3,975)
Beta-Blocker
Group
(n ¼ 2,650)
No–Beta-Blocker
Group
(n ¼ 1,325)
Adjusted
HR* (95% CI) p Value
All-cause death 74 (2.8) 54 (4.1) 0.46 (0.27–0.78) 0.004
Cardiac death 40 (1.5) 37 (2.8) 0.39 (0.19–0.79) 0.01
Myocardial infarction 30 (1.1) 19 (1.4) 0.61 (0.28–1.36) 0.23
All-cause death or MI 101 (3.8) 70 (5.3) 0.60 (0.40–0.91) 0.02
Any coronary
revascularization
141 (5.3) 85 (6.4) 0.85 (0.59–1.22) 0.38
Major adverse
cardiac eventsy
219 (8.3) 140 (10.6) 0.78 (0.59–1.02) 0.07
Values are n (%) unless otherwise indicated. *Adjusted covariates include age, sex, infarct-
related artery, number of coronary arteries narrowed, pre-procedural TIMI ﬂow grade on culprit
vessel, use of glycoprotein IIb/IIIa inhibitor, and beta-blocker at discharge. yMajor adverse
cardiac events included all-cause death, recurrent MI, and any coronary revascularization with
PCI or coronary artery bypass graft.
Abbreviations as in Tables 1 to 3.
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598reﬂect the early association of beta-blocker therapy with the
clinical outcomes of STEMI, because only stable outpatients
were selectively enrolled in this registry and there were no
data on onset, type, and risk proﬁle of MI (20). Therefore, in
the present study, we investigated the associations of beta-
blocker therapy at discharge with clinical outcomes using
data from the nationwide MI registries of Korea, and we
demonstrate that beta-blocker therapy at discharge was
associated with beneﬁts to mortality in STEMI patients
undergoing primary PCI. A large sample size and reﬂection
of current real-world practice such as high rates of use of
statins, renin-angiotensin system blockades, or dual anti-
platelet therapy are the strengths of our study.
Considering that beta-blockers have anti-ischemic, anti-
arrhythmic, and antiadrenergic properties (17,21,22), ourFigure 3. Kaplan-Meier Curves in Beta-Blocker Versus No–Beta-Blocker Groups i
(A) Kaplan-Meier curves for all-cause death in beta-blocker (solid line) versus no–beta
events (MACE) in beta-blocker (solid line) versus no–beta-blocker (dashed line) groresults appear to be relevant. However, patients who did
not receive beta-blockers in the present study were charac-
terized as having relatively high-risk factors such as older
age, Killip class III on admission, and low left ventricular
ejection fractions. Therefore, the observed beneﬁt of beta-
blockers in our study may result from differences in
baseline characteristics. To address this, we performed
propensity score-matching to adjust for the differences in
baseline characteristics between the groups. After propensity
score-matching, baseline characteristics were well balanced
between the groups, and the result was consistent in all
patients and propensity-matched populations. Moreover,
patients who died during the index hospitalization were
not included by study design in the present study, which
reduced possible bias due to differences in baseline charac-
teristics between the groups. Taken together, the association
with better outcome of beta-blocker therapy in terms of all-
cause mortality cannot be attributed to differences in base-
line characteristics between the 2 groups. It is uncertain why
there were no signiﬁcant differences between the groups
in the incidences of MI and revascularization. Unrestricted
use of drug-eluting stents, complete revascularization, and
medication other than beta-blockers such as statins, renin-
angiotensin system blockades, or dual antiplatelet therapy
may explain the low and similar incidences of MI and
revascularization in both groups.
Although the association of beta-blocker therapy with
better outcome was reported to be greatest in the relatively
high-risk group with low ejection fraction or multivessel
coronary artery disease (4), the implications of long-term
beta-blocker therapy in relatively low-risk patients has not
been well established. In the present study, the association of
beta-blocker therapy with better outcome was consistent,
and there were no signiﬁcant interactions between use
of beta-blockers at discharge and death across variousn Propensity-Matched Populations
-blocker (dashed line) groups. (B) Kaplan-Meier curves for major adverse cardiac
ups.
Figure 4. Comparative Unadjusted Hazard Ratios of All-Cause Death for Subgroups in Overall Populations
CI ¼ conﬁdence interval; LAD ¼ left anterior descending artery; LVEF ¼ left ventricular ejection fraction.
Figure 5. Comparative Unadjusted Hazard Ratios of All-Cause Death for Subgroups in Propensity-Matched Populations
Abbreviations as in Figure 4.
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600subgroups. Statistical signiﬁcance was found in patients
with left ventricular ejection fraction >40%, Killip class I
or II, and single-vessel disease in whom the association
with better outcome of beta-blocker therapy has not been
demonstrated in previous studies (4,5). The large sample
size of our study made subgroup analysis possible and
demonstrated the association with better outcome of beta-
blocker therapy in these populations. Although the ﬁndings
are hypothesis-generating, our results support the current
ACC/AHA guidelines, which recommend long-term
beta-blocker therapy in all patients with STEMI regardless
of risk proﬁle.
Study limitations. First, the study lacks data on speciﬁc
beta-blockers and doses. Also, we do not know how long
beta-blockers continued to be taken after discharge. Second,
the nonrandomized nature of the registry data could have
resulted in selection bias. Although we performed propensity
score-matched analysis to adjust for these potential con-
founding factors, we were not able to correct for unmeasured
variables. In particular, we did not have information on
several important variables such access site and comorbidities
such as cancer, history of asthma, or chronic obstructive
pulmonary disease due to the limitations of the databases.
However, the association with better outcome of beta-
blocker therapy was demonstrated in terms of cardiac mor-
tality as well as all-cause mortality in the present study.
Large-scale, prospective, randomized-controlled trials are
needed to clarify the effects of long-term beta-blocker
therapy in patients with STEMI undergoing primary PCI.
Third, adverse clinical events were not centrally adjudicated
in our registries. All events were identiﬁed by the patient’s
physician and conﬁrmed by the principal investigator of
each hospital. Considering the limitation of possible inac-
curacy in determining cause of death, we selected “all-cause
mortality” as the primary outcome instead of “cardiac
mortality.” Finally, the clinical data encompassed a
12-month period in KAMIR and a 24-month period in
the KorMI registry. A median follow-up of 12 months
may be too short for conclusive determination of the long-
term efﬁcacy of beta-blockers in the setting of STEMI.
Accordingly, the long-term prognostic outcomes of the
2 groups beyond 1 year after the index event remain un-
clear because median follow-up duration was approxi-
mately 1 year.
Conclusions
Beta-blocker therapy at discharge was associated with
improved survival in patients with STEMI undergoing
primary PCI. Our results support the current ACC/AHA
guidelines, which recommend long-term beta-blocker ther-
apy for all patients with STEMI regardless of reperfusion
therapy or risk proﬁle.Acknowledgments
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